Avutometinib Clinical Trials (2026): 21 Studies for KRAS Activating Mutation & Non Small Cell Lung Cancer

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

21 Avutometinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 18 indications (including KRAS Activating Mutation & Non Small Cell Lung Cancer) and 1,486 total planned enrollment. 1 Phase 3 Avutometinib trial and 11 Phase 2 are listed. 12 Avutometinib clinical trials are actively recruiting at 71 U.S. sites across 24 states. Most recent activity: NCT06072781 (Feb 2031).

Where to Participate: All Avutometinib Trial Sites in the U.S. (71 sites across 24 states)

Every actively recruiting Avutometinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
AZHonorHealthPhoenix85016NCT06072781Map
ARUniversity of ArkansasLittle Rock72205NCT06072781Map
CAUCLA HealthLos Angeles90095NCT06072781Map
CAUC DavisSacramento95817NCT06072781Map
CAUniversity of California, San FranciscoSan Francisco94143NCT06072781Map
CTYale UniversityNew Haven06520NCT06072781Map
FLFlorida Cancer Specialists - SouthFort Myers33901NCT06072781Map
FLMount SinaiMiami Beach33140NCT06072781Map
FLAdventHealthOrlando32804NCT05512208Map
FLAdventHealthOrlando32804NCT06072781Map
FLMoffitt Cancer CenterTampa33612NCT06072781Map
FLFlorida Cancer Specialists Research EastWest Palm Beach33401NCT06072781Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT06495125Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06495125Map
GAEmory Winship Cancer InstituteAtlanta30322NCT06394804Map
GAWinship Cancer Institute at Emory UniversityAtlanta30322NCT06072781Map
ILNorthShore University HealthSystemEvanston60201NCT06072781Map
IAUniversity of IowaIowa City52242NCT06194929Map
LALouisiana State UniversityNew Orleans70112NCT06072781Map
LALouisiana State University Medical Center New OrleansNew Orleans70112NCT05512208Map
MDSidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore21287NCT06072781Map
MIKarmanos Cancer CenterDetroit48201NCT06072781Map
MNMinnesota Oncology HematologyMinneapolis55404NCT06072781Map
MOWashington University School of MedicineSt Louis63110NCT06072781Map
MOWashington University School of MedicineSt Louis63110NCT07126158Map
NJMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT05787561Map
NJMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT06007924Map
NJMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT06394804Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT05787561Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT06007924Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT06394804Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT05787561Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06007924Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06394804Map
NMUniversity of New Mexico Comprehensive Cancer CenterAlbuquerque87131NCT05512208Map
NYRoswell Park Cancer InstituteBuffalo14263NCT06072781Map
NYMemorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)Commack11725NCT06007924Map
NYMemorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities)Commack11725NCT05787561Map
NYMemorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities)Commack11725NCT06394804Map
NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison10604NCT05787561Map
NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison10604NCT06007924Map
NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison10604NCT06394804Map
NYColumbia University Irving Medical CenterNew York10032NCT06487221Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05787561Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06072781Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06394804Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT06007924Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre11553NCT06007924Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale11553NCT05787561Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale11553NCT06394804Map
NCAtrium HealthCharlotte28203NCT06072781Map
OHCleveland Clinic FoundationCleveland44195NCT06072781Map
OHOhio StateHilliard43026NCT06072781Map
OKStephenson Cancer CenterOklahoma City73117NCT05512208Map
OKUniversity of Oklahoma Medical CenterOklahoma City73104NCT06072781Map
ORWillamette Valley Cancer InstituteEugene97401NCT06072781Map
ORNorthwest Cancer SpecialistsPortland97227NCT06072781Map
PAAsplundh Cancer Pavilion | Jefferson HealthPhiladelphia19090NCT06072781Map
PAAllegheny Health NetworkPittsburgh15224NCT06072781Map
TXTexas Oncology CentralAustin78731NCT06072781Map
TXTexas Oncology-Fort Worth Cancer CenterFort Worth76104NCT06072781Map
TXHouston MethodistHouston77030NCT06072781Map
TXMD Anderson Cancer CenterHouston77030NCT06072781Map
TXMD Anderson Cancer CenterHouston77807NCT06369259Map
TXTexas OncologySan Antonio78229NCT06072781Map
TXTexas OncologyThe Woodlands77380NCT06072781Map
TXTexas OncologyTyler75702NCT06072781Map
UTIntermountain Medical CenterMurray84107NCT06072781Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT06194929Map
VAUniversity of Virginia Health SystemCharlottesville22908NCT06072781Map
VAVirginia Cancer Specialists, PCGainesville20155NCT06072781Map

Avutometinib clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedsuspendednot yet recruitingTotal
Early P111
P1112
P1/P22316
P282111
P311

Recruiting Avutometinib clinical trials (12)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06072781RAMP 301A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerP3Low Grade Serous Ovarian Cancer270Mar 2024
NCT066302605G-RUBY5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursP1/P2Glioblastoma Multiforme (GBM)182Nov 2024
NCT07318324Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerP1Phase IB31Jun 2026
NCT07126158Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaP2Pancreatic Adenocarcinoma36Apr 2026
NCT06194929DETERMINEDefactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaP1/P2Cutaneous Melanoma33Mar 2024
NCT05512208DURAFAKA Phase 2 Study of Avutometinib (VS-6766) Plus DefactinibP2Endometrioid Cancer55Feb 2023
NCT06495125Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerP2Advanced Lung Adenocarcinoma50Jul 2024
NCT06487221Avutometinib and Defactinib in Diffuse Gastric CancerP2Gastric Cancer27Oct 2024
NCT06369259Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerP2Advanced Colorectal Cancer33Feb 2025
NCT06007924A Study of Avutometinib and Defactinib in People With Thyroid CancerP2Thyroid Cancer30Aug 2023
NCT06394804CHAMELEONA Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerP2Low-Grade Serous Ovarian Cancer20Apr 2024
NCT05787561VS-6766A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerP2Mesonephric Gynecologic Cancer40Mar 2023

Avutometinib clinical trials by indication

Non Small Cell Lung Cancer (3)

NCTAcronymPhaseStatusTitle
NCT05074810RAMP203P1/P2active not recruitingPhase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05375994RAMP204P1/P2active not recruitingStudy of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT04620330RAMP202P2completedA Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Low Grade Serous Ovarian Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06072781RAMP 301P3recruitingA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06682572RAMP201JP2active not recruitingA Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Phase IB (1)

NCTAcronymPhaseStatusTitle
NCT07318324P1not yet recruitingPhase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Pancreatic Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07126158P2recruitingStereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Advanced Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06369259P2recruitingOpen-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Glioblastoma Multiforme (GBM) (1)

NCTAcronymPhaseStatusTitle
NCT066302605G-RUBYP1/P2recruiting5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Gastric Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06487221P2recruitingAvutometinib and Defactinib in Diffuse Gastric Cancer

Advanced Lung Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06495125P2recruitingDefactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Low-Grade Serous Ovarian Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06394804CHAMELEONP2recruitingA Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Cutaneous Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT06194929DETERMINEP1/P2recruitingDefactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Refractory Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06104488P1active not recruitingA Study of Avutometinib for People With Solid Tumor Cancers

Thyroid Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06007924P2recruitingA Study of Avutometinib and Defactinib in People With Thyroid Cancer

Glioblastoma (1)

NCTAcronymPhaseStatusTitle
NCT05798507Early P1active not recruitingIdentification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

KRAS Activating Mutation (1)

NCTAcronymPhaseStatusTitle
NCT05669482RAMP205P1/P2active not recruitingStudy of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Mesonephric Gynecologic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05787561VS-6766P2recruitingA Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Endometrioid Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05512208DURAFAKP2recruitingA Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05200442P1/P2suspendedA Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Low Grade Ovarian Serous Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04625270RAMP 201P2active not recruitingA Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Avutometinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
RAMP 301NCT06072781P3recruitingLow Grade Serous Ovarian Cancer270PMID 39375168
DURAFAKNCT05512208P2recruitingEndometrioid Cancer55
RAMP201JNCT06682572P2active not recruitingLow Grade Serous Ovarian Cancer16
CHAMELEONNCT06394804P2recruitingLow-Grade Serous Ovarian Cancer20
VS-6766NCT05787561P2recruitingMesonephric Gynecologic Cancer40
RAMP 201NCT04625270P2active not recruitingLow Grade Ovarian Serous Adenocarcinoma225PMID 38493021
RAMP202NCT04620330P2completedNon Small Cell Lung Cancer90PMID 35285277

Terminated and withdrawn Avutometinib trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

All Avutometinib trials (21)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06072781RAMP 301A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerP3recruiting270Verastem, Inc.Mar 2024
NCT066302605G-RUBY5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursP1/P2recruiting182Institute of Cancer Research, United KingdomNov 2024
NCT07318324Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerP1not yet recruiting31M.D. Anderson Cancer CenterJun 2026
NCT07126158Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaP2recruiting36Washington University School of MedicineApr 2026
NCT06194929DETERMINEDefactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaP1/P2recruiting33University of UtahMar 2024
NCT05512208DURAFAKA Phase 2 Study of Avutometinib (VS-6766) Plus DefactinibP2recruiting55University of OklahomaFeb 2023
NCT06104488A Study of Avutometinib for People With Solid Tumor CancersP1active not recruiting3Memorial Sloan Kettering Cancer CenterOct 2023
NCT06495125Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerP2recruiting50Emory UniversityJul 2024
NCT06487221Avutometinib and Defactinib in Diffuse Gastric CancerP2recruiting27Ryan H. Moy, MD, PhDOct 2024
NCT06369259Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerP2recruiting33M.D. Anderson Cancer CenterFeb 2025
NCT05798507Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaEarly P1active not recruiting14Emory UniversityJul 2023
NCT06682572RAMP201JA Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsP2active not recruiting16Verastem, Inc.Oct 2024
NCT05669482RAMP205Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerP1/P2active not recruiting40Verastem, Inc.Mar 2023
NCT06007924A Study of Avutometinib and Defactinib in People With Thyroid CancerP2recruiting30Memorial Sloan Kettering Cancer CenterAug 2023
NCT05200442A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal CancerP1/P2suspended53University of ChicagoAug 2022
NCT06394804CHAMELEONA Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerP2recruiting20Memorial Sloan Kettering Cancer CenterApr 2024
NCT05074810RAMP203Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsP1/P2active not recruiting153Verastem, Inc.Apr 2022
NCT05787561VS-6766A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerP2recruiting40Memorial Sloan Kettering Cancer CenterMar 2023
NCT04625270RAMP 201A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationP2active not recruiting225Verastem, Inc.Dec 2020
NCT05375994RAMP204Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsP1/P2active not recruiting85Verastem, Inc.Aug 2022
NCT04620330RAMP202A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerP2completed90Verastem, Inc.Dec 2020

Avutometinib clinical trials: frequently asked questions

How many Avutometinib clinical trials are there?
21 Avutometinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 11 are actively recruiting participants. 1 is marked completed.
Are Avutometinib clinical trials recruiting in 2026?
Yes — 11 Avutometinib trials are actively recruiting in 2026, with 71 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Avutometinib being studied for?
Avutometinib is being studied for KRAS Activating Mutation, Non Small Cell Lung Cancer, Ovarian Cancer, Low Grade Serous Ovarian Cancer, Metastatic Cancer and 56 more. The trials are grouped by indication on this page.
What phase is Avutometinib in?
Avutometinib clinical trials span 1 Phase 3, 11 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Avutometinib clinical trials?
The lead sponsor across the most Avutometinib trials is Verastem, Inc., with 9 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Avutometinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: